Acquisition by Kevin Conroy of 708 shares of EXACT Sciences at 30.02 subject to Rule 16b-3
| EXAS Stock | USD 61.23 0.06 0.1% |
Slightly above 54% of EXACT Sciences' investor base is interested to short. The analysis of current outlook of investing in EXACT Sciences suggests that many traders are impartial regarding EXACT Sciences' prospects. EXACT Sciences' investing sentiment can be driven by a variety of factors including economic data, EXACT Sciences' earnings reports, geopolitical events, and overall market trends.
Filed transaction by EXACT Sciences Director, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
EXACT Sciences Fundamental Analysis
We analyze EXACT Sciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EXACT Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EXACT Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
EXACT Sciences is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
EXACT Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with EXACT Sciences stock to make a market-neutral strategy. Peer analysis of EXACT Sciences could also be used in its relative valuation, which is a method of valuing EXACT Sciences by comparing valuation metrics with similar companies.
Peers
EXACT Sciences Related Equities
| RDY | Dr Reddys | 1.62 | ||||
| ROIV | Roivant Sciences | 0.88 | ||||
| VTRS | Viatris | 0.69 | ||||
| BAX | Baxter International | 0.52 | ||||
| QGEN | Qiagen NV | 0.29 | ||||
| IONS | Ionis Pharmaceuticals | 0.03 | ||||
| BBIO | BridgeBio Pharma | 0.20 | ||||
| ILMN | Illumina | 0.47 | ||||
| RVTY | Revvity | 0.54 | ||||
| GH | Guardant Health | 2.98 |
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.